These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 18316585)
21. Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Ghatak S; Hascall VC; Berger FG; Penas MM; Davis C; Jabari E; He X; Norris JS; Dang Y; Markwald RR; Misra S Connect Tissue Res; 2008; 49(3):265-9. PubMed ID: 18661357 [TBL] [Abstract][Full Text] [Related]
22. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Ladewig K; Niebert M; Xu ZP; Gray PP; Lu GQ Biomaterials; 2010 Mar; 31(7):1821-9. PubMed ID: 19922997 [TBL] [Abstract][Full Text] [Related]
23. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Chang RS; Suh MS; Kim S; Shim G; Lee S; Han SS; Lee KE; Jeon H; Choi HG; Choi Y; Kim CW; Oh YK Biomaterials; 2011 Dec; 32(36):9785-95. PubMed ID: 21937102 [TBL] [Abstract][Full Text] [Related]
24. Nonviral delivery vehicles for use in short hairpin RNA-based cancer therapies. Vorhies JS; Nemunaitis J Expert Rev Anticancer Ther; 2007 Mar; 7(3):373-82. PubMed ID: 17338656 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104 [TBL] [Abstract][Full Text] [Related]
26. Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A. Mook OR; Baas F; de Wissel MB; Fluiter K Cancer Gene Ther; 2009 Jun; 16(6):532-8. PubMed ID: 19165236 [TBL] [Abstract][Full Text] [Related]
27. Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles. Wong Y; Markham K; Xu ZP; Chen M; Max Lu GQ; Bartlett PF; Cooper HM Biomaterials; 2010 Nov; 31(33):8770-9. PubMed ID: 20709387 [TBL] [Abstract][Full Text] [Related]
28. Convenient targeting of stealth siRNA-lipoplexes to cells with chelator lipid-anchored molecules. Herringson TP; Altin JG J Control Release; 2009 Nov; 139(3):229-38. PubMed ID: 19595724 [TBL] [Abstract][Full Text] [Related]
29. Delivery of nanoparticulate drug delivery systems via the intravenous route for cancer gene therapy. Hallaj-Nezhadi S; Lotfipour F; Dass CR Pharmazie; 2010 Dec; 65(12):855-9. PubMed ID: 21284252 [TBL] [Abstract][Full Text] [Related]
30. A peptide-targeted delivery system with pH-sensitive amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery. Wang XL; Xu R; Lu ZR J Control Release; 2009 Mar; 134(3):207-13. PubMed ID: 19135104 [TBL] [Abstract][Full Text] [Related]
31. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Hua D; Liu MY; Cheng ZD; Qin XJ; Zhang HM; Chen Y; Qin GJ; Liang G; Li JN; Han XF; Liu DX Mol Immunol; 2009 Sep; 46(15):2876-84. PubMed ID: 19643479 [TBL] [Abstract][Full Text] [Related]
32. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant therapy with small hairpin RNA interference prevents non-small cell lung cancer metastasis development in mice. Bulk E; Hascher A; Liersch R; Mesters RM; Diederichs S; Sargin B; Gerke V; Hotfilder M; Vormoor J; Berdel WE; Serve H; Müller-Tidow C Cancer Res; 2008 Mar; 68(6):1896-904. PubMed ID: 18339871 [TBL] [Abstract][Full Text] [Related]
34. Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours. Kenny GD; Villegas-Llerena C; Tagalakis AD; Campbell F; Welser K; Botta M; Tabor AB; Hailes HC; Lythgoe MF; Hart SL Biomaterials; 2012 Oct; 33(29):7241-50. PubMed ID: 22809644 [TBL] [Abstract][Full Text] [Related]
35. Nanoparticle and targeted systems for cancer therapy. Brannon-Peppas L; Blanchette JO Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294 [TBL] [Abstract][Full Text] [Related]
36. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene. Vigne S; Germi R; Duraffour S; Larrat S; Andrei G; Snoeck R; Garin D; Crance JM Antivir Ther; 2008; 13(3):357-68. PubMed ID: 18572748 [TBL] [Abstract][Full Text] [Related]
37. Nanotechnology for in vivo targeted siRNA delivery. Dahlman JE; Kauffman KJ; Langer R; Anderson DG Adv Genet; 2014; 88():37-69. PubMed ID: 25409603 [TBL] [Abstract][Full Text] [Related]
38. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery. Singh SK; Hajeri PB Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929 [TBL] [Abstract][Full Text] [Related]
39. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Dorer DE; Nettelbeck DM Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376 [TBL] [Abstract][Full Text] [Related]
40. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Davis ME Mol Pharm; 2009; 6(3):659-68. PubMed ID: 19267452 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]